PLAT and Stroke: For example, use of the modified pediatric ASPECTS could expedite eligibility determination in intervention trials that require stratification by infarct size, such as the planned dose finding and safety study of intravenous recombinant tissue plasminogen activator in pediatric stroke (Amlie-Lefond et al., 2009).